Company Overview
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Why Investors Should Care
Net profit has compounded at 43.8% per year over the last five years.
Revenue has grown at a 17.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $194.06M (+25.3% YoY); net profit $14.35M.
- Trailing 12 Months Year-on-year growth — revenue -1.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.7%, profit CAGR 43.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.69% |
| 1 Year: | -1.40% |
Compounded Profit Growth
| 5 Years: | 43.84% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -60.16% |
| 6 Months: | +16.84% |
| 3 Months: | +15.35% |
| 1 Month: | -7.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.7% over 5 years.
- Profit CAGR of 43.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 63.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LFMD LifeMD, Inc. R2K | 4.51 | -10.25 | $218.11M | 0.00% | -26.60% | - | 17.69% | 43.84% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.70M | 2.70M | 3.13M | 4.30M | 9.09M | 11.01M | 18.20M | 22.31M | 24.95M | 29.04M | 30.46M | 31.41M | 33.13M | 35.95M | 38.61M | 44.14M | 50.66M | - | - | 50.89M | 62.22M | 60.17M | 7.08M | 50.16M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.14M | 7.43M | 7.41M | 4.23M | 5.93M |
| Gross Profit | 52.31K | 143.34K | 127.45K | 93.86K | 214.06K | 187.85K | 205.90K | 303.09K | 526.27K | 996.23K | 79.73K | 474.99K | 1.52M | 1.25M | 1.50M | 2.06M | 1.99M | 2.04M | 2.45M | 2.97M | 7.40M | 9.33M | 14.99M | 18.19M | 19.85M | 23.79M | 25.82M | 26.70M | 28.91M | 31.40M | 33.83M | 39.54M | 45.64M | - | - | 42.75M | 54.79M | 52.76M | 2.85M | 44.24M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.93M | 55.69M | 54.73M | 9.07M | 53.17M |
| Operating Income | -168.67K | -177.64K | -75.38K | -132.94K | 7.83K | -17.17K | 17.94K | -105.10K | -153.63K | -207.70K | -401.79K | -380.30K | -273.57K | -279.31K | -938.45K | -438.63K | -563.37K | -833.16K | -973.71K | -1.74M | -3.22M | -20.53M | -11.92M | -16.13M | -12.59M | -13.11M | -12.90M | -7.07M | -2.85M | -4.90M | -4.57M | -6.17M | -6.31M | - | - | -1.18M | -906.77K | -1.97M | -6.22M | -8.93M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 509.69K | 2.88M | -133.33K | -6.22M | -6.93M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 558.60K | - | 626.27K | 663.03K | 262.46K | -190.79K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.65M | -1.57M | -3.39M | -6.03M | -8.87M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 169.48K | 0 | - | 169.13K | -123.41K | 0 |
| Net Income | -139.37K | -140.94K | -71.50K | -103.90K | 1.67K | -21.03K | 8.12K | -62.05K | -199.98K | -226.65K | -1.04M | 737.49K | -679.06K | 627.28K | -1.05M | -548.98K | -663.75K | -818.10K | -943.80K | -2.39M | -3.38M | -20.62M | -11.60M | -16.83M | -14.35M | -13.30M | -13.02M | -7.28M | -4.01M | -6.73M | -6.12M | -6.77M | -6.88M | - | - | -183.78K | -2.07M | -3.81M | 19.96M | -8.87M |
| Diluted EPS | - | - | - | - | 31,363,306.00 | 30,650,000.00 | 30,650,000.00 | 32,010,375.00 | -0.01 | -0.01 | - | 0.02 | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.01 | -0.06 | -0.10 | 0.41 | -0.20 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 673.78K | 808.36K | 714.16K | 1.22M | 5.24M | 3.68M | 42.52K | 12.47M | 37.29M | - | 119.03M | 152.55M | 154.82M | 194.06M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 18.67M | 18.90M | 21.44M | 27.71M |
| Gross Profit | 473.87K | 627.06K | 541.31K | 971.09K | 3.29M | 2.66M | 6.33M | 9.94M | 28.43M | - | 100.37M | 133.65M | 133.38M | 166.34M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 140.05M | 148.14M | 153.79M | 174.01M |
| Operating Income | -540.02K | -546.41K | -530.88K | -262.22K | -1.17M | -1.23M | -2.06M | -2.89M | -57.82M | - | -39.69M | -14.49M | -20.40M | -7.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -35.92M | -7.89M | -14.21M | -1.52M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 2.18M | 1.36M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -44.66M | -17.41M | -22.58M | -10.19M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 360.70K | 428.00K | 598.00K | 45.72K |
| Net Income | -445.65K | -268.26K | -460.49K | -61.99K | -1.11M | -1.21M | -1.24M | -3.14M | -58.65M | - | -45.54M | -20.60M | -21.41M | 14.35M |
| Diluted EPS | - | - | - | - | -0.03 | -0.03 | - | - | - | - | -1.57 | -0.70 | -0.53 | 0.25 |
| R&D Expense | - | - | - | 23.93K | - | - | - | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Sep 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Sep 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 369.69K | 551.45K | 175.22K | - | 448.47K | 789.82K | 1.26M | 2.62M | 3.45M | 13.40M | 49.92M | 25.67M | 58.48M | 76.10M | 70.41M |
| Total Equity | -282.98K | - | 135.00K | 195.49K | -139.50K | - | 100.08K | -355.17K | 881.92K | 897.70K | -988.18K | -2.30M | 22.74M | -11.40M | 3.51M | -9.08M | 23.16M |
| Cash & Equivalents | 33.50K | 163.18K | 98.93K | 155.06K | 75.50K | 73.86K | 232.98K | 182.56K | 141.38K | 180.09K | 1.11M | 9.18M | 41.33M | 3.96M | 33.15M | 35.00M | - |
| Total Liabilities | - | - | 234.70K | 355.96K | 314.72K | - | 267.48K | - | 640.97K | 1.80M | 4.58M | 14.22M | 24.10M | 32.97M | 52.91M | 83.65M | 47.25M |
| Current Liabilities | - | - | 187.10K | 325.56K | 301.52K | - | 267.48K | 1.15M | 640.97K | 1.19M | 3.98M | 13.93M | 22.83M | 31.37M | 34.78M | 67.40M | 41.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -229.73K | -259.07K | 33.44K | -295.12K | -407.91K | -817.22K | -905.52K | 251.41K | -12.13M | -33.09M | -22.94M | 8.82M | 17.51M | 8.28M |
| Investing Cash Flow | - | - | - | - | - | - | 141.44K | -100.00K | -798.14K | -3.40M | -13.91M | -8.73M | -11.54M | 6.91M |
| Financing Cash Flow | 295.15K | 315.20K | -113.00K | 325.35K | 357.49K | 776.03K | 802.79K | 775.12K | 21.00M | 68.64M | -528.20K | 29.10M | -4.12M | -13.41M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | -247.37K | -366.63K | -203.81K | -1.46M | -1.87M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | -33.33M | -23.30M | 8.62M | 16.05M | 6.41M |
| Share Buybacks | - | - | - | - | - | 76.65K | - | - | - | - | - | - | - | 270.00K |
| Dividends Paid | - | - | - | - | - | - | - | - | - | 871.48K | 3.11M | 3.11M | 3.11M | 3.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 70.3% | 77.6% | 75.8% | 79.7% | 62.9% | 72.4% | 14,883.9% | 79.7% | 76.2% | - | 84.3% | 87.6% | 86.2% | 85.7% |
| Operating Margin % | -80.1% | -67.6% | -74.3% | -21.5% | -22.4% | -33.4% | -4,836.3% | -23.2% | -155.0% | - | -33.3% | -9.5% | -13.2% | -4.0% |
| Net Margin % | -66.1% | -33.2% | -64.5% | -5.1% | -21.1% | -32.8% | -2,918.6% | -25.2% | -157.3% | - | -38.3% | -13.5% | -13.8% | 7.4% |
| ROE % | -330.1% | -137.2% | 330.1% | -61.9% | 311.8% | -136.7% | -138.2% | 317.5% | 2,547.8% | - | 399.6% | -587.6% | 235.7% | 62.0% |
| ROCE % | -295.7% | -241.9% | 420.3% | -144.9% | 324.7% | -197.2% | -144.4% | 546.0% | 10,920.8% | - | 695.2% | -61.1% | -234.6% | -26.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.81% | 2.81M | $13.76M |
| 2 | Vanguard Capital Management LLC | 3.44% | 1.66M | $8.15M |
| 3 | Royce & Associates LP | 2.48% | 1.20M | $5.89M |
| 4 | Renaissance Technologies, LLC | 2.31% | 1.12M | $5.48M |
| 5 | State Street Corporation | 2.22% | 1.08M | $5.27M |
| 6 | Federated Hermes, Inc. | 2.11% | 1.02M | $4.99M |
| 7 | Geode Capital Management, LLC | 2.11% | 1.02M | $5.00M |
| 8 | Prescott Group Capital Management, L.L.C. | 1.85% | 895.42K | $4.39M |
| 9 | Brc Group Holdings, Inc. | 1.80% | 871.58K | $4.27M |
| 10 | Susquehanna International Group, LLP | 0.96% | 465.19K | $2.28M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LFMD
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOek85M09ObFJvSHlXZ0pOcEx4WDVwblFJVzVydFFpNmhmd2FHanlHMy02ZGNHaDFsY0c5Vk9SejRNTTV6cmVpU2NFMjQxS3B3TDFRN0hyMGNqaEFKUHdqSTdVbG5lTHBRODRnNUlGa0lRdzhrT3B1Z2VwMDR1UWhTWUlHWFZiQTlXR2NMTU…
LifeMD, Halozyme link up to sell testosterone therapy online - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQRkthaVVibmxVd3VmTVR6MnJ5eEpPTUgxMm53SFhZVkNsd3lsN3NzbVpMVVlyc0F3RGpXM3hmNU1ESWdXdDh5ZWdBSlNOVmpQQURqZWdjUnJncWNRMkE1Nlp4d1dyZ19tVHpQcm01X2hSTktUZzF4Y1VnTnFhakJJSUNLd3FsSUI4VWt0en…
B.Riley reiterates LifeMD stock Buy rating on telehealth expansion - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOeEY2MTI1NzVwV2xfYnkwVnlHZWVKcGF4aHJveldHd2NEOEFqVnlySFpJRFFBQ3RzMDRkbXU1SWMwVVhSTXlwd1A4ZVhnZE5sUzRHWGhGLWlJQmI1VEx3Q3RubllPd2NJckVYTUJrdUQxQkFwb3hWOUoxVU45UUtGT2Fmc2hBdWZoUC1VUX…
LIFEMD ($LFMD) Releases Q4 2025 Earnings, Stock Rises | LFMD Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNTHNsRmxiWTBmTmlVRkJKd0pvbVM2ZnZneExZdEZSbXRuLVl3Vml5NExqdndUTmtfd29DTU5USWZiMkZrTFdtUjdOSTBzcWVLbDRLOTRMOWJhVzQ1dDJURl91YmdBQ3lXTDc1eUg1R0VSMFdWa2tkSHVzempIUG5iRVY3OEdmeEZ0TURvYj…
Why Investors Shouldn't Be Surprised By LifeMD, Inc.'s (NASDAQ:LFMD) 31% Share Price Plunge - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQbGNKVW9oNmEwNEdoakJab016dnBnSDB2XzJIOFFUaTNnUU1IRHBkRTEzbjdpaE96eVNyb1dqVHFOZ0RQdWg3N3U3X2RXUUcyTHZaWHc1STRuWVB0bGNKX1B4TUw2UnRRa09mUm1ZZXZTb1FqaDhEc2xyOFQ2VG1vWWd3ZXFoQWVQdEZQa2…
LifeMD: A Growing Healthcare Tech Stock, As Q1 Results Confirm Patient Demand - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPYjZTemNEbEdKQ0ZmOE1TaFE5bTFReUV5SmlPazBuZUZGdHVGLW41ZTBvMHE4cDVPRFZyVFEwMGItN2ppMkhFWUVnZ2xsQjRvamRaVjFOSE80NlMyNGlyaVdXc0xFQmVicG5YbkJuUUhiN3hqQW50bVVVYWJFckY1WGNjaF9rR1B4TVluNz…
LFMD — Frequently Asked Questions
What is the current share price of LifeMD, Inc. (LFMD)?
As of 2026-07-14 21:23 PDT, LifeMD, Inc. (LFMD) trades at $4.51 on NasdaqGM. Its 52-week range is $2.64 to $12.35.
What is the market capitalisation of LFMD?
LifeMD, Inc. (LFMD) has a market capitalisation of $218.11M on NasdaqGM.
What is the P/E ratio of LFMD?
LFMD trades at a trailing price-to-earnings (P/E) ratio of -10.25. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 14.87.
Is LFMD a good stock to buy?
This page provides a data-driven analysis of LifeMD, Inc. (LFMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.